Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock

Critical Care Medicine

Volumn 42, Issue 8, 2014, Pages 1812-1820

  Anantasit, Nattachai ^a   Boyd, John H ^a,b   Walley, Keith R ^a,b   Russell, James A ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

arginine vasopressin receptor 1b; norepinephrine; septic shock; serious adverse events; vasopressin

Indexed keywords

ARGIPRESSIN RECEPTOR; ARGIPRESSIN RECEPTOR 1B; HYPERTENSIVE FACTOR; NORADRENALIN; UNCLASSIFIED DRUG; VASOPRESSIN; ARGININE VASOPRESSIN RECEPTOR 1B, HUMAN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR;

ADULT; APACHE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OUTCOME VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; TEACHING HOSPITAL; VASOPRESSIN BLOOD LEVEL; AGED; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; RETROSPECTIVE STUDY; RISK FACTOR; SHOCK, SEPTIC; SURVIVAL RATE; VALIDATION STUDY;

AGED; AREA UNDER CURVE; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, VASOPRESSIN; RETROSPECTIVE STUDIES; RISK FACTORS; SHOCK, SEPTIC; SURVIVAL RATE; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 84904759579     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000333     Document Type: Article

References (27)

1. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39:165-228
2. Obritsch MD, Bestul DJ, Jung R, et al: The role of vasopressin in vaso-dilatory septic shock. Pharmacotherapy 2004; 24:1050-1063
3. Obritsch MD, Jung R, Fish DN, et al: Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 2004; 38:1117-1122
4. Dünser MW, Mayr AJ, Tür A, et al: Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. Crit Care Med 2003; 31:1394-1398
5. Russell JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887
6. Hall LG, Oyen LJ, Taner CB, et al: Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy 2004; 24:1002-1012
7. Ferguson-Myrthil N: Vasopressor use in adult patients. Cardiol Rev 2012; 20:153-158
8. Annane D, Vignon P, Renault A, et al; CATS Study Group: Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: A randomised trial. Lancet 2007; 370:676-684
9. Torgersen C, Dünser MW, Wenzel V, et al: Comparing two different arginine vasopressin doses in advanced vasodilatory shock: A randomized, controlled, open-label trial. Intensive Care Med 2010; 36:57-65
10. van Haren FM, Rozendaal FW, van der Hoeven JG: The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003; 124:2256-2260
11. Holmes CL, Walley KR, Chittock DR, et al: The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 2001; 27:1416-1421
12. Phillips KA, Veenstra DL, Oren E, et al: Potential role of pharmacoge-nomics in reducing adverse drug reactions: A systematic review. JAMA 2001; 286:2270-2279
13. Russell JA: Bench-to-bedside review: Vasopressin in the management of septic shock. Crit Care 2011; 15:226
14. Nakada TA, Russell JA, Wellman H, et al: Leucyl/cystinyl aminopepti-dase gene variants in septic shock. Chest 2011; 139:1042-1049
15. Nakada TA, Russell JA, Boyd JH, et al: Beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med 2010; 181:143-149
16. Wu CK, Tsai CT, Chang YC, et al: Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. J Hypertens 2009; 27:502-507
17. Nakada TA, Russell JA, Boyd JH, et al: Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med 2011; 39:1641-1648
18. Bone RC, Balk RA, Cerra FB, et al: Defnitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
19. Sutherland AM, Walley KR, Manocha S, et al: The association of inter-leukin 6 haplotype clades with mortality in critically ill adults. Arch Intern Med 2005; 165:75-82
20. Sibbald WJ, Vincent JL: Round table conference on clinical trials for the treatment of sepsis. Intensive Care Med 1995; 21:184-189
21. Groesdonk HV, Klingele M, Schlempp S, et al: Risk factors for nonoc-clusive mesenteric ischemia after elective cardiac surgery. J Thorac Cardiovasc Surg 2013; 145:1603-1610
22. Hernando F, Schoots O, Lolait SJ, et al: Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: Anatomical support for its involvement in the central effects of vasopressin. Endocrinology 2001; 142:1659-1668
23. LolaitSJ, StewartLQ, JessopDS, etal:Thehypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 2007; 148:849-856
24. Sharshar T, Blanchard A, Paillard M, et al: Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752-1758
25. Xu S, Guo S, Jiang X, et al: The role of norepinephrine and nitric oxide in activities of rat arginine vasopressin neurons in response to immune challenge. Neurosci Lett 2005; 383:231-235
26. Delmas A, Leone M, Rousseau S, et al: Clinical review: Vasopressin and terlipressin in septic shock patients. Crit Care 2005; 9:212-222
27. Leng G, Brown CH, Russell JA: Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol 1999; 57:625-655